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The cancer immunoediting hypothesis has gained significant footing over the past decade as a result of work performed using
sarcomas induced by 3-methylcholanthrene (3-MCA) in mice. Despite the progress made by several groups in establishing evidence
for the three phases of immunoediting (elimination, equilibrium and escape), there continues to be active controversy on the nature
of interaction between spontaneously formed tumour cells and the immune system during the early phases of tumourigenesis. At the
root of this controversy is conflicting and unresolved evidence spanning back to the 1970s regarding the incidence and frequency of
3-MCA-induced sarcomas in immunocompetent mice as compared to immunodeficient mice. In this mini review we provide a critical
analysis of both sides of this controversy.
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Tumour immunosurveillance is the process through which the
innate and adaptive immune systems identify and eliminate self-
cells that have become transformed through spontaneous,
chemically or virally induced genetic alterations. The concept of
tumour immunosurveillance has endured many false starts over
the past century, but the framework first articulated by Burnet and
Thomas in the late 1950s (Burnet, 1957), has been supported by
numerous reports over the past decade. One of the earliest known
studies that linked immune activation to cancer regression was
conducted by William Coley beginning in 1893. Later known as
‘Coley’s toxin’, the killed mixture of Streptococcus pyogenes and
Serratia marcescens was used in a number of clinical trials up
through the 1980s. The most robust of these studies demonstrated
clinical benefits for the treatment of hepatocellular carcinoma,
nodular lymphoma and various inoperable tumours that failed to
reach statistical significance (Johnston and Novales, 1962;
Johnston, 1962; Tang et al, 1991). The most apparent therapy
used today that descended from Coleys toxin is with the use of
Bacillus Calmette-Guerin for the treatment of bladder cancer.
The pace of research in understanding tumour/immune inter-
actions slowed significantly in the late 1970s, following a report in
Science by Osias Stutman (Stutman, 1974). In this report, the rate
and frequency of sarcoma formation following chemical induction
with 3-methylcholanthrene (3-MCA) was investigated in immuno-
competent and athymic mice. The results of this study were
devastating, and showed that there was no difference in either the
time required for tumours to develop, or the overall tumour
frequency, in immunocompetent mice as compared to athymic
mice. The observation that immunodeficient mice and immuno-
competent mice were equally susceptible to chemically induced
tumour formation was a substantial obstacle for Burnet and
Thomas’ immunosurveillance hypothesis to overcome. This mini
review is written from the sidelines of the controversy surrounding
3-MCA-induced sarcomas. From this vantage point an attempt is
made to reveal areas in which the reinterpretation of experimental
design and results may guide future studies that will ultimately
settle ‘the immunosurveillance controversy’ and fortify the
foundation of the ‘immunoediting hypothesis’.
CLINICAL AND EXPERIMENTAL SUPPORT FOR
TUMOUR IMMUNOSURVEILLANCE
Clinical data began to emerge in the mid 1980s and through the
1990s both from solid organ and bone marrow transplant
recipients and from HIV/AIDS patients that supported a role for
the immune system in preventing tumour growth. Early in the
onset of the AIDS epidemic, several groups began to report on the
high frequency of Kaposi’s sarcoma in immunocompromised
patients (Pape et al, 1983; Haverkos and Drotman, 1985). The
incidence of Kaposi’s sarcoma among men with AIDS decreased
from 40% in 1981 to 20% in 1992, but still remains the most
common AIDS-associated cancer in the United States (Biggar and
Rabkin, 1996). Kaposi’s sarcoma is also associated with immuno-
suppression following solid organ transplantation, with an overall
risk of 0.5% (Farge, 1993). These data support the concept that the
immune system can actively suppress the outgrowth of latent
tumours, but it is important to note that immune control of virally
induced tumours has not been a controversial issue. Other cancers
with an increased risk following immunosuppression and organ
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www.bjcancer.comtransplantation include kidney, bladder, malignant melanoma,
liver, colon, cervical, prostate, breast, pancreatic, brain, thyroid,
bone and connective tissue (Curtis et al, 1997; Kasiske et al, 2004).
It was not until the mid 1990s that new evidence began to
emerge from several laboratories, in additional support to the
clinical data that reinvigorated the pursuit of understanding the
immune control of cancer. The generation of perforin-1 knockout
mice (Kagi et al, 1994), led to a series of studies demonstrating
that mice with a profound defect in cell-mediated cytotoxicity
are more susceptible to chemically induced tumour formation
(van den Broek et al, 1996), rapid tumour growth (van den Broek
et al, 1996; Smyth et al, 1998) and tumour metastasis (Smyth et al,
1999). These reports clearly demonstrated a role for adaptive
immunity in the control of cancer, and were coincident
with reports in PNAS and then Nature, by Robert Schreiber’s
group, that flew directly in the face of the 1974 paper by
Osias Stutman (Kaplan et al, 1998; Shankaran et al, 2001).
These experiments substantially advanced the evidence that
adaptive immunity helps control tumour formation by showing
that in addition to perforin-1, IFN-g, STAT-1 and T cells all
contribute to reducing 3-MCA-induced tumour formation and
growth. Furthermore, Shankaran et al, demonstrated for the
first time that tumours which grew in immunodeficient mice
were more immunogenic than tumours arising in immuno-
competent mice, which fortified Burnet and Thomas’ original
theory of immunosurveillance and led to the formal articulation of
the immunoediting hypothesis in 2002 (Dunn et al, 2002). At the
same time tumour-specific antigens were identified in a number of
different tumour models, providing for the first time a mechanistic
basis for adaptive immune destruction of transformed cells (Van
den Eynde and van der Bruggen, 1997; Van Der Bruggen et al,
2002). The immunoediting hypothesis consists of three main
phases of tumour/immune interactions: elimination (the first
phase, during which immunogenic tumour cells are killed by
infiltrating immune cells often eliminates all transformed cells, but
may occasionally leave a population of cells behind that are less
‘visible’ to the immune system), equilibrium (the second phase,
during which the growth of the tumour is roughly equal to the
immune system’s ability to control it has a variable duration, in
some cases spanning the life of the individual) and escape (the
final phase, when a combination of reduced immunogenicity,
acquisition of immune suppressor mechanisms or through the
development of more rapid growth potential the tumour is capable
of outpacing an immune response).
THE (LACK OF) CONSENSUS IN THE LITERATURE
Since these reports, the Schreiber group and others have
continued to advance the understanding of immunoediting,
equilibrium and escape; however, the discrepancies between
3-MCA-induced tumour formation in the Stutman report and
in the Shankaran report have yet to be resolved. More importantly,
there is a lack of independent reports which specifically address
the incidence of 3-MCA-induced sarcomas in immunocompetent
and immunodeficient mice, to validate Shankaran et al, and
the few reports that have been published by investigators
attempting to duplicate those data have resulted in a bona fide
controversy (Engel et al, 1997; Qin and Blankenstein, 2004). In a
2004 Nature correspondence, Qin and Blankenstein provide
evidence that is reminiscent of Stutman’s work, demonstrating
that the rate and frequency of 3-MCA-induced tumour formation
is similar between RAG-1
/ or perforin-1
/ mice and immuno-
competent mice. In addition to Stutman and Blankenstein, a report
by Noguchi et al also found no difference in the incidence
of tumours between immunocompetent and immunodeficient
mice, although this finding was not emphasised in the report
(Noguchi et al, 1996). Table 1 provides a summary of published
studies examining tumour formation following chemical induction
by 3-MCA.
After comparing these results, it is first important to note that no
two studies can be directly compared because at least one critical
parameter (3-MCA dose, injection site or strain of mice used) differs
between studies. Individual doses may be compared among the van
den Broek, Kaplan and Cretney studies, but this comparison reveals
the heterogeneity in tumour formation by identical strains of mice
to equal dose and injection protocols of 3-MCA (Kaplan et al, 1998;
Cretney et al, 2002; Table 1; Figure 1). Van den Broek et al,K a p l a n
et al, Cretney et al and Qin et al have all published intrastudy dose
response effects for 3-MCA-induced tumour formation (Qin et al,
2002). Taken independently, each of these studies demonstrate a
3-MCA dose-dependent increase of sarcoma formation, and in each
study the difference in tumour formation between immunocompe-
tent and immunodeficient mice is lost at the highest dose (van den
Broek et al, 1996; Kaplan et al, 1998; Cretney et al, 2002; Hayakawa
et al, 2003). An interstudy comparison obscures these differences
(Figure 1). Although these studies all agree that the greatest
difference in tumour formation between immunocompetent and
immunodeficient mice is observed at the lowest dose (25mg), one
study shows that this difference is completely lost at the
intermediate dose (100mg), whereas another suggests that the
difference is actually increased. In C57BL/6 mice, the difference in
tumour incidence between wild-type and perforin-1-deficient mice
drops from 0.8 with a dose of 25mg 3-MCA to 0.2 with a dose of
100mg 3-MCA, whereas in 129/SvEv mice the difference is stable at
doses of 25 and 100mg 3-MCA (0.26 and 0.29, respectively).
Shankaran et al also used a dose of 100mg 3-MCA, and reported a
difference in tumour incidence of B0.4, with even the most severely
immunocompromised group forming tumours only 72% of the
time. Interestingly, reports from the same laboratory, using the
same strains of mice and method of 3-MCA administration
demonstrate interexperimental variability of as much as 35%
(Kaplan et al compared to Shankaran et al). This degree of
interexperimental variability raises concerns regarding studies that
selectively pooled data from several large experiments for multiple
publications (Smyth, 2008). The Stutman study also used a dose of
100mg 3-MCA; however, the strain of mice in this study was CBA/H,
and no significant difference in tumour formation was reported
between immunocompetent and immunodeficient mice. Two factors
that also inhibit direct comparisons between the Stutman study and
others are (1) animals were injected with 3-MCA as neonates and (2)
the time to follow-up was significantly shorter than other studies.
Even studies by the same laboratory, Shankaran et al and Koebel
et al (Koebel et al, 2007) or Qin et al and Qin and Blankenstein,
cannot be directly compared because the two studies differ both in
the dose of 3-MCA and the strains of mice used. Value may be
derived without comparing, however, given the data illustrating a
3-MCA dose-response, the data suggest that C57BL/6 mice may be
substantially more susceptible to 3-MCA-induced tumour formation
because 18% of immunocompetent C57BL/6 mice formed progres-
sively growing tumours before day 100, whereas it took immuno-
competent 129/SvEv mice 4150 days to reach the same incidence
with a 4-fold higher dose of 3-MCA (or a 16-fold higher dose for the
Blankenstein studies).
In addition to significant differences in tumour formation
depending on the dose of 3-MCA and strain of mice used, the route
of injection or the use of littermates as controls may also play a
significant role. Qin and Blankenstein use an identical dose of 3-MCA
and strain of mice to van den Broek et al; however, the route of
injection varies, intramuscular and subcutaneous, respectively. This
suggests that the route of injection may alter tumour formation by as
much as 60% in immunocompetent mice. The use of littermates as
controls, as well as restriction of comparisons to animals maintained
within identical housing parameters, has been suggested as an
addition precaution to reduce the observed variability in 3-MCA-
induced tumour formation (Blankenstein and Qin, 2003).
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Yet another variable that may confound the reported differences
between studies and between immunocompetent and immuno-
deficient mice may arise from reporting the percentage of tumour-
free mice compared to reporting tumour growth curves. Stutman,
van den Broek, Smyth (Smyth et al, 2005), Cretney, Hayakawa,
Noguchi, Kaplan and Qin all report percentages of tumour-free
mice (or tumour incidence), whereas the two papers from the
Schreiber group, Shankaran and Koebel, provide data for
Table 1 Summary of tumour formation following chemical induction by 3-methylcholanthrene by various studies
Study
3-MCA
dose (lg)
Route of
injection
Mouse
strain
Tumour
incidence
Earliest
tumour (day)
Median time to
tumour formation
(days)
Time to
follow-up
(days)
Stutman (1974) 100 Subcutaneous CBA/H 0.13 87 98 120
nu/nu (CBA) 0.18 80 90 120
van den Broek et al (1996) 25 Subcutaneous C57BL/6 0.2 100
a 4200 200
perforin-1
/ (C57BL/6) 1 60
a 75
a 200
100 Subcutaneous C57BL/6 0.8 95
a 160
a 200
CD8
/ (C57BL/6) 0.8 95
a 160
a 200
perforin-1
/ (C57BL/6) 1 60
a 80
a 200
400 Subcutaneous C57BL/6 1 85
a 90
a 200
perforin-1
/ (C57BL/6) 1 40
a 50
a 200
Noguchi et al (1996) 25 Subcutaneous BALB/cBy 1 70
a 98
a 210
CB-17 SCID 1 70
a 77
a 140
100 Subcutaneous BALB/cBy 1 35
a 91
a 175
Kaplan et al (1998) 25 Subcutaneous 129/SvEv 0.02 dnp dnp 165
IFNGR1
/(129/SvEv) 0.28 90
a dnp 165
STAT1
/(129/SvEv) 0.21 dnp dnp 165
100 Subcutaneous 129/SvEv 0.1 100
a dnp 165
IFNGR1
/(129/SvEv) 0.39 90
a dnp 165
STAT1
/(129/SvEv) 0.5 dnp dnp 165
400 subcutaneous 129/SvEv 0.53 100
a dnp 165
IFNGR1
/(129/SvEv) 0.5 90
a 130
a 165
Shankaran et al (2001) 100 Subcutaneous 129/SvEv 0.19 125
a dnp 160
RAG2
/(129/SvEv) 0.58 85
a dnp 160
IFNGR1
/(129/SvEv) 0.6 dnp dnp 160
STAT1
/(129/SvEv) 0.57 dnp dnp 160
RkSk(129/SvEv) 0.72 dnp dnp 160
Cretney et al (2002) 5 Subcutaneous C57BL/6 0.05
a 120
a n/a 180
TRAIL
/ (C57BL/6) 0.3
a 105
a n/a 180
25 Subcutaneous C57BL/6 0.15 110
a n/a 180
TRAIL
/ (C57BL/6) 0.5
a 90
a 170
a 180
100 Subcutaneous C57BL/6 0.2 105
a n/a 180
TRAIL
/ (C57BL/6) 0.7 90
a 105
a 180
400 Subcutaneous C57BL/6 0.8
a 95
a 110
a 180
TRAIL
/ (C57BL/6) 1 95
a 95
a 180
Qin et al (2002) 100 Intramuscular IFNGR1
+/(129/SvEv) 0.4
a 210
a n/a 560
IFNGR1
/(129/SvEv) 0.8
a 154
a 203
a 560
300 Intramuscular IFNGR1
+/(129/SvEv) 0.6
a 203
a 350
a 560
IFNGR1
/(129/SvEv) 1 112
a 196
a 560
800 Intramuscular IFNGR1
+/(129/SvEv) 0.8
a 126
a 231
a 560
IFNGR1
/(129/SvEv) 1 84
a 161
a 560
Hayakawa et al (2003) 400 Subcutaneous C57BL/6 0.9 80 115 250
IFNg
/ (C57BL/6) 1 75 110 250
perforin-1
/ (C57BL/6) 1 80 110 250
TRAIL
/ (C57BL/6) 1 75 95 250
Qin and Blankenstein
(2004)
25 Intramuscular C57BL/6 0.8 91
a 119
a 210
RAG1
+/(C57BL/6) 0.8 98
a 112
a 210
RAG1
/(C57BL/6) 0.9 91
a 105
a 210
C57BL/6 0.9 112
a 126
a 350
perforin-1
/ (C57BL/6) 1 105
a 119
a 140
Smyth et al (1998, 1999,
2005)
25 Subcutaneous C57BL/6 0.2
a 120
a n/a 200
RAG1
/(C57BL/6) 0.8
a 70
a 95
a 200
IFNg
/ (C57BL/6) 0.5
a 80
a 105
a 200
perforin-1
/ (C57BL/6) 0.5
a 75
a 105
a 200
TRAIL
/ (C57BL/6) 0.5
a 90
a 105
a 200
Koebel et al (2007) 25 Subcutaneous C57BL/6 40.18 92
a dnp 300
5 Subcutaneous RAG1
/(C57BL/6) 40.16 79
a 105
a 300
Tumour incidence refers to the percentage of mice developing tumours over the course of the study. Earliest tumour refers to the number of days that elapsed between the time
of 3-MCA injection and the first palpable tumour. Median time to tumour formation refers to the number of days that elapsed between the time of 3-MCA injection and the time
at which 50% of mice developed tumours. ‘dnp’ indicates that the authors of the study did not provide this information; ‘n/a’ indicates that data was not available because 50% of
mice did not form tumours.
aThe value was estimated based on graphs provided by the authors, where the exact date was not provided.
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potential reason for these differences in their report, providing
elegant evidence for the role of adaptive immunity in ‘maintaining
occult cancer in an equilibrium state’. These authors consider mice
with masses smaller than B0.3cm
2, ‘tumour-free’. As other
authors do not provide evidence of tumour size, it is not possible
to determine whether similar parameters were set, or whether
small nodules were counted as tumours regardless of size or
kinetics of growth. If this ‘tumour-free’ assumption was applied to
previous reports on plots showing the percentage of tumour-free
mice, it would likely lead to curves for immunocompetent mice
with a more gradual slope.
The impact of this definition may be assessed by examining the
changes in the results presented by Koebel et al if all masses,
regardless of size, were scored as tumours. These studies utilised
C57BL/6 mice injected subcutaneously with a dose of 25mg 3-MCA.
If mice with masses less than B0.3cm
2 are scored as ‘tumour-free’,
the overall incidence for immunocompetent mice is 0.18 and 0.21
for the two groups followed up to 200 days. If the tumour
incidence in the same group of mice is assessed regardless of the
size of the mass, the tumour incidence increases from 0.18 to 0.56
and from 0.21 to 0.47 in the two groups of immunocompetent
mice. In this study the immunodeficient group of mice were
injected with a lower dose (5mg/ml) of 3-MCA, so direct
comparisons cannot be drawn between the immunocompetent
and immunodeficient groups. Regardless, the interstudy variability
illustrated in Table 1 suggests that the application of a separate
analytical filter which alters the tumour incidence between 2- and
3-fold is a potential explanation for otherwise irreconcilable data
between investigators.
REFINING THE IMMUNOEDITING HYPOTHESIS
The crux of the argument provided by Qin and Blankenstein
antagonising immunosurveillance of autochthonous tumours is
not that immunosurveillance does not occur, but that subclinical
tumours induce immune tolerance, rather than evolving through a
process of immunoselection. Although current analysis of the
literature falls short of resolving this controversy, it is tempting to
speculate that elements of both theories may be true on a case-by-
case basis for chemically induced tumours. Due to the hetero-
geneity of 3-MCA-induced sarcomas in immunocompetent mice, a
few being rapidly progressive and the majority developing to a
small size and eventually being either rejected or displaying late
spontaneous outgrowth, it is highly likely that the immune
response to these tumours is also heterogeneous. Rapidly
progressive sarcomas may acquire an array of genetic mutations
that impart a particularly aggressive phenotype capable of out-
pacing an immune response in an immunocompetent animal.
These rapidly progressing tumours may also never acquire
particularly immunogenic mutations, and therefore remain below
the threshold of immune detection. Tumours, which develop
slowly in immunocompetent mice and endure a period of
‘equilibrium’ with the immune system may eventually develop
sufficient clonal antigenicity to engage an immune response. This
immune response may then either lead to elimination of the
tumour, or may be overcome by the tumour either via the
induction of tolerance, the acquisition of local and/or systemic
immunosuppressive elements by the tumour or by an increased
proliferative capacity resulting from additional genetic mutations.
Another observation made by Koebel et al is the lag time in
immunocompetent mice between the emergence of rapidly
growing tumours and the times at which ‘stable’ tumours emerge.
There appears to be a ‘tumour-free’ period of about 40 days
between the rapidly growing tumours and the stable masses. It
would be expected that within a given tissue, a specific chemical
insult would have a predictable lag time between the insult and the
average time at which tumours emerged, and that the emergence of
tumours following that lag time would follow a Gaussian
distribution. However, the data clearly indicate a bimodal
distribution of tumour incidence with an early peak of aggressive
tumours and a delayed peak of less-aggressive, immunogenic
tumours. Therefore, it is possible that most mice, both immuno-
competent and immunodeficient, develop tumours at equivalent
time points following a given inoculation with 3-MCA, but that
immunocompetent mice are capable of eliminating the majority of
transformed cells at this early time point (even before a tumour
nodule is palpable), which may or may not reemerge following
clonal expansion and enter a period of immune equilibrium.
In contrast to chemically induced tumours, virally induced
cancers result from the prolonged expression of viral proteins,
many of which are highly immunogenic, and must necessarily
evade immune elimination either by the induction of tolerance, the
loss of immunogenicity or, as in the case of Kaposi’s sarcoma,
remain latent until an immunoprivileged opportunity arises
(Luppi et al, 2000; Scadden, 2003; Kannagi, 2007). Two impressive
examples of how viruses can evolve to manipulate the immuno-
genicity of the cells they infect are KSHV (HHV-8) and HTLV-1.
KSHV is able to establish long-term infection of the human host
because of the functions of the proteins encoded by the virus.
Specifically, KSHV-encoded vFLIP and vIRF-1 enable the virus to
differentially regulate MHC-I transcription, allowing the virus to
maintain an immune stalemate, which protects both the host and
the virus from destruction (Lagos et al, 2007). In the case of
HTLV-1, the virally encoded Tax protein directs a multitude
of intracellular functions promoting the survival and proliferation
of infected cells, but it is also a powerful antigen in the evolution of
an anti-HTLV-1 immune response; indeed, progression from
chronic HTLV-1 infection to adult T-cell leukaemia often coincides
with the reduced expression of the Tax protein (Kannagi, 2007).
Autochthonous tumours are inherently different from virally
induced tumours in that spontaneous tumours develop mutations
over time, which may or may not result in the presentation of an
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Figure 1 Tumour incidence was plotted for three doses of 3-MCA from the data in Table 1. Strains of mice and routes of injection are not distinguished
in this figure. Furthermore, all immunodeficient knockout mouse models displayed in Table 1 are lumped together as ‘immunodeficient’ in this figure. Error
bars are ±s.e.m.
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tumours have been developed recently, and have begun to
illustrate the importance of innate immune surveillance and
editing of emerging tumours. Using models of spontaneous
prostatic adenocarcinoma and B-cell lymphoma, Guerra et al
(2008) illustrate that mice deficient in the natural-killer cell
receptor, NKG2D, develop earlier and more aggressive disease than
the immunocompetent mice. These authors also show that the
aggressive tumours developed in NKG2D-deficient mice express
higher levels of NKG2D ligands (which mediate NK-mediated
destruction of some tumour cells) than the tumour cells from wild-
type mice, suggesting that in immunocompetent mice one of the
early events in the immunoediting of spontaneous tumours may be
the selection of tumour-cell variants that express low levels of
NKG2D ligands.
The hypothesis that both spontaneous and virally induced
tumours can be recognised and controlled by the immune system
is now clearly supported both by clinical and laboratory data
(Farge, 1993; Curtis et al, 1997; Luppi et al, 2000; Scadden, 2003;
Kasiske et al, 2004; Kannagi, 2007; Lagos et al, 2007). Furthermore,
the idea that tumour development in an immunocompetent animal
proceeds through a variable sequence of immunologic checkpoints
involving tolerance induction, immunoselection, immune evasion
and/or immune elimination has been well supported by experi-
mentation with 3-MCA-induced sarcomas (van den Broek et al,
1996; Kaplan et al, 1998; Smyth et al, 1999; Shankaran et al, 2001;
Dunn et al, 2002; Koebel et al, 2007). The resolution to this
controversy will likely require larger scale studies by multiple
investigators using identical chemical dosing and delivery proto-
cols, in identical strains of immunocompetent and immunodefi-
cient mice. A major goal of these studies should be to narrow the
predicted range of sarcoma formation at individual 3-MCA doses
(Figure 1), such that comparisons between immunocompetent and
immunodeficient mice may be validated. Given the importance of
tumour-specific or -associated antigens in the generation of
antitumour immune responses, these studies should also be
performed using a system where antigens may be defined and
tracked throughout the development of spontaneous or chemically
induced tumours, techniques for which have been described
(Willimsky et al, 2008). The criteria for categorising ‘tumour-free’
mice must also be clarified. Furthermore, recent work with
spontaneous tumour models suggests that the role of the innate
immune system in controlling tumour formation may be under-
appreciated by chemically induced models of tumour formation
(Guerra et al, 2008), so future studies should seek to incorporate
elements of both systems to fully appreciate the immune control of
cancer. Even after these studies are performed, it is highly likely
that some tumours will be found to induce early immune
tolerance, some will develop independent of immune regulation
and some will run the proposed gauntlet of immune elimination,
equilibrium and eventually escape.
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